Medication use among Australian adults with intellectual disability in primary healthcare settings: A cross-sectional study

References

• Ahmed, Z., Fraser, W., Kerr, M. P., Kiernan, C., Emerson, E., Roberston, J., Felce, D., …Thomas, J. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 176, 42–46. doi: 10.1192/bjp.176.1.42
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (1997). Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154(Suppl. 4), 1–63.
   Web of Science ®Google Scholar
• Branford, D. (1996). A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Journal of Intellectual Disability Research, 40, 358–368.
   PubMed Web of Science ®Google Scholar
• de Bildt, A., Mulder, E. J., Scheers, T., Minderaa, R. B., & Tobi, H. (2006). Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation. Pediatrics, 118, e1860–e1866.
   PubMed Web of Science ®Google Scholar
• Fisher, K. (2004). Health disparities and mental retardation. Journal of Nursing Scholarship, 36, 48–53. doi: 10.1111/j.1547-5069.2004.04010.x
   PubMed Web of Science ®Google Scholar
• Freeman, M. P., Fava, M., Lake, J., Trivedi, M. H., Wisner, K. L., & Mischoulon, D. (2010). Complementary and alternative medicine in major depressive disorder: The American Psychiatric Association Task Force report. Journal of Clinical Psychiatry, 71, 669–681. doi: 10.4088/JCP.10cs05959blu
   PubMed Web of Science ®Google Scholar
• Haukka, J., Suvisaari, J., Tuulio-Henriksson, A., & Lönnqvist, J. (2007). High concordance between self-reported medication and official prescription database information. European Journal of Clinical Pharmacology, 63, 1069–1074. doi: 10.1007/s00228-007-0349-6
   PubMed Web of Science ®Google Scholar
• Holden, B., & Gitlesen, J. P. (2004). Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices. Research in Developmental Disabilities, 25, 509–521. doi: 10.1016/j.ridd.2004.03.004
   PubMed Web of Science ®Google Scholar
• Janicki, M. P., Davidson, P. W., Henderson, C. M., McCallion, P., Taets, J. D., Force, L. T., …Ladrigan, P. M. (2002). Health characteristics and health services utilization in older adults with intellectual disability living in community residences. Journal of Intellectual Disability Research, 46, 287–298. doi: 10.1046/j.1365-2788.2002.00385.x
   PubMed Web of Science ®Google Scholar
• Lennox, N., Bain, C., Rey-Conde, T., Purdie, D., Bush, R., & Pandeya, N. (2007). Effects of a comprehensive health assessment programme for Australian adults with intellectual disability: A cluster randomized trial. International Journal of Epidemiology, 36, 139–146. doi: 10.1093/ije/dyl254
   PubMed Web of Science ®Google Scholar
• Lennox, N., Bain, C., Rey-Conde, T., Taylor, M., Boyle, F. M., Purdie, D. M., & Ware, R. S. (2010). Cluster randomized-controlled trial of interventions to improve health for adults with intellectual disability who live in private dwellings. Journal of Applied Research in Intellectual Disabilities, 23, 303–311. doi: 10.1111/j.1468-3148.2009.00533.x
   Web of Science ®Google Scholar
• MacLennan, A. H., Wilson, D. H., & Taylor, A. W. (2002). The escalating cost and prevalence of alternative medicine. Preventive Medicine, 35, 166–173. doi: 10.1006/pmed.2002.1057
   PubMed Web of Science ®Google Scholar
• Matson, J. L., & Neal, D. (2009). Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities, 30, 572–586. doi: 10.1016/j.ridd.2008.08.007
   PubMed Web of Science ®Google Scholar
• McGillivray, J. A., & McCabe, M. P. (2006). Emerging trends in the use of drugs to manage the challenging behaviour of people with intellectual disability. Journal of Applied Research in Intellectual Disabilities, 19, 163–172. doi: 10.1111/j.1468-3148.2005.00251.x
   Web of Science ®Google Scholar
• Molyneux, P., Emerson, E., & Caine, A. (1999). Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. Journal of Applied Research in Intellectual Disabilities, 12, 46–57. doi: 10.1111/j.1468-3148.1999.tb00049.x
   Web of Science ®Google Scholar
• Nøttestad, J. A., & Linaker, O. M. (2003). Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research, 47, 464–471. doi: 10.1046/j.1365-2788.2003.00511.x
   PubMed Web of Science ®Google Scholar
• Rønning, M. (2001). Coding and classification in drug statistics – from national to global application. Norwegian Journal of Epidemiology, 11, 37–40.
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry, 39, 1–30.
   PubMed Web of Science ®Google Scholar
• Ryan, M. (1991). Drug use in N.S.W. institutions: Innovation for inertia. Australia and New Zealand Journal of Developmental Disabilities, 17, 177–181.
   Google Scholar
• Sachdev, P. S. (1991). Psychoactive drug use in an institution for intellectually handicapped persons. Medical Journal of Australia, 155, 75–79.
   PubMed Web of Science ®Google Scholar
• Singh, N. N., Ellis, C. R., & Wechsler, H. (1997). Psychopharmacoepidemiology of mental retardation: 1966 to 1995. Journal of Child and Adolescent Psychopharmacology, 7, 255–266. doi: 10.1089/cap.1997.7.255
   PubMed Web of Science ®Google Scholar
• Sivakumar, P. (2007). Metabolic syndrome and intellectual disability [Correspondence]. The British Journal of Psychiatry, 191, 364. doi: 10.1192/bjp.191.4.364a
   PubMed Web of Science ®Google Scholar
• Tranulis, C., Skalli, L., Lalonde, P., Nicole, L., & Stip, E. (2008). Benefits and risks of antipsychotic polypharmacy: An evidence-based review of the literature. Drug Safety, 31, 7–20. doi: 10.2165/00002018-200831010-00002
   PubMed Web of Science ®Google Scholar
• Vahabzadeh, A. B. N., Delaffon, V., & Biswas, A. B. (2010). Meeting the health care needs of people with learning disabilities. InnovAiT, 3, 328–332. doi: 10.1093/innovait/inq054
   Google Scholar
• World Health Organization. (2009). Guidelines for ATC classification and DDD assignment 2010. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology.
   Google Scholar